Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients

PURPOSE: Oxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to oxymorphone by CYP2D6. The aim of this study was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Toyoda, Masanori, Chayahara, Naoko, Kiyota, Naomi, Shimada, Takanobu, Imamura, Yoshinori, Mukohara, Toru, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133207/
https://www.ncbi.nlm.nih.gov/pubmed/25121773
http://dx.doi.org/10.1371/journal.pone.0104215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133207/
https://www.ncbi.nlm.nih.gov/pubmed/25121773
http://dx.doi.org/10.1371/journal.pone.0104215

Ejemplares similares